Buy Ariadne Cas 52842-58-7

Buy Ariadne Cas 52842-58-7

Ariadne, also known chemically as 4C-D or 4C-DOM, by its developmental code name BL-3912, and by its former tentative brand name Dimoxamine, is a non-hallucinogenic psychoactive drug of the phenethylamine, phenylisobutylamine (α-ethylphenethylamine), and 4C families.^{[5][1][2][6][7]} It is a close analogue of the psychedelic drugs 2C-D and DOM, with 2C-D having no substitution at the α carbon, DOM having an α-methyl group, and Ariadne having an α-ethyl group.^[5][1][2][6] Ariadne is taken orally.^[1][2]

The drug is a serotonin 5-HT₂ receptor partial agonist, including of the serotonin 5-HT_2A receptor, similarly to psychedelics.^[5] However, Ariadne is not hallucinogenic in humans, but is still psychoactive, producing antidepressant and mild stimulant effects such as feelings of well-being and mental alertness.^[5][1][2][8] The drug shows dopaminergic actions in animals, such as increased motivation and reversal of parkinsonism, which may be mediated by serotonin 5-HT_2A receptor activation-induced dopamine release in the brain.^[5][1] It is thought that the non-psychedelic nature of Ariadne with retained psychoactive effects is due to reduced but still high efficacy at the serotonin 5-HT_2A receptor relative to psychedelics.^[5]

Ariadne was first synthesized by Alexander Shulgin in 1968 and its psychoactive effects were discovered by Shulgin in 1969.^[8][5][1] It was developed as a potential pharmaceutical drug at Bristol Laboratories, for instance as an antidepressant and for various other uses, and entered clinical trials around 1974.^[8][5][6][2] The drug reached phase 3 trials prior to its development being shelved.^[8] The development of Ariadne is said to have been discontinued for strategic economic reasons rather than due to issues with effectiveness or safety.^[8][5] There has been renewed interest in Ariadne and similar drugs in the 2020s owing to increased interest in psychedelics for treatment of psychiatric disorders.^[5] Ariadne is not an explicitly controlled substance in the United States, but may be considered Schedule I as an isomer of DOET.^[2]

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin reported human tests of Ariadne at doses of up to 32 mg orally, finding that it produced “the alert of a psychedelic, with none of the rest of the package”.^[1] Very little published data exists about the human pharmacology of Ariadne apart from Shulgin’s limited testing; unpublished human trials reportedly observed some psychoactive effects, but no hallucinogenic effects.^[9][5] Ariadne is one of Shulgin’s “ten classic ladies“, a series of methylated DOM derivatives.^[1][10]

In his book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, Shulgin described (R)-Ariadne as increasing mental alertness and producing feelings of well-being at doses of 25 to 50 mg orally.^[2] It was claimed to improve symptoms of manic depression in psychotic individuals at doses of 50 to 100 mg orally and to improve symptoms of Parkinson’s disease at a dosage of 100 mg/day orally.^[2][5] Doses of up to 300 mg resulted in an altered state of consciousness but still no psychedelic effects.^[5][2] For comparison, DOM shows psychoactive sub-hallucinogenic effects at doses of 1 to 3 mg orally and psychedelic effects at doses of more than 3 mg orally.^[5]

The effects of Ariadne have been said to have a duration of 2 to 5 hours.^[4]

Another related drug with similar psychoactive effects as Ariadne is thiobuscaline.^[1]

Ariadne, as the (R)- enantiomer, is active at doses as low as 25 mg and was tested in clinical trials at doses of 50 to 100 mg.^[5] Doses as high as 300 mg have been assessed, more than 10 times higher than the minimum reported active dose.^[5] No psychedelic effects occurred at this or lower doses, but therapeutic effects were observed.^[5]

Ariadne activities

Target	Affinity (Ki, nM)
5-HT1A	>10,000 (Ki) 656 (EC50Tooltip half-maximal effective concentration) 68% (EmaxTooltip maximal efficacy)
5-HT1B	>10,000 (Ki) 4,023 (EC50) 90% (Emax)
5-HT1D	ND (Ki) 612 (EC50) 65% (Emax)
5-HT1E	ND (Ki) 727 (EC50) 79% (Emax)
5-HT1F	ND (Ki) 690 (EC50) 75% (Emax)
5-HT2A	120 (Ki) 39–1,300 (EC50) 80–97% (Emax)
5-HT2B	>10,000 (Ki) 217–>32,000 (EC50) 68–85% (Emax)
5-HT2C	ND (Ki) 120–3,020 (EC50) 34–93% (Emax)
5-HT3	>10,000
5-HT4	ND (Ki) ND (EC50) <20% (Emax)
5-HT5A	ND (Ki) ND (EC50) <20% (Emax)
5-HT6	ND (Ki) 1,038 (EC50) 42% (Emax)
5-HT7	ND (Ki) ND (EC50) <20% (Emax)
α1A	>10,000
α1B, α1D	ND
α2A	>10,000
α2B, α2C	ND
β1, β2	>10,000
β3	ND
D1, D2	>10,000
D3–D5	ND
H1, H2	>10,000
H3, H4	ND
M1–M3	>10,000
M4, M5	ND
I1	ND
σ1, σ2	ND
TAAR1Tooltip Trace amine-associated receptor 1	ND
SERTTooltip Serotonin transporter	>10,000 (Ki) >50,000 (IC50Tooltip half-maximal inhibitory concentration) ND (EC50)
NETTooltip Norepinephrine transporter	>10,000 (Ki) ND (IC50) ND (EC50)
DATTooltip Dopamine transporter	>10,000 (Ki) >100,000 (IC50) ND (EC50)
MAO-ATooltip Monoamine oxidase A	>10,000 (Ki)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [11][5][12][13]

Ariadne is a potent and selective agonist of the serotonin 5-HT₂ receptors, including of the serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors.^[5][12][13] However, it is less efficacious in activating the serotonin 5-HT_2A receptor, including the G_q, G₁₁, and β-arrestin2 signaling pathways, compared to the related drug DOM, and this weaker partial agonism may be responsible for its lack of psychedelic effects.^[5][12] In addition to the serotonin 5-HT₂ receptors, Ariadne is a lower-affinity agonist of the serotonin 5-HT₁ receptors.^[5] Ariadne shows essentially no activity at the monoamine transporters.^[5]

Ariadne shows a markedly attenuated head-twitch response, a behavioral proxy of psychedelic effects, in animals, although it does still significantly induce a weak head-twitch response.^[5][12][14] The drug substitutes for DOM in rodent drug discrimination tests, albeit with dramatically lower potency than DOx drugs like DOM itself, DOET, and DOB.^[14] It has also been shown to produce stimulus generalization in rats trained to respond to LSD^[9] and MDMA.^[15] Ariadne’s capacity to fully substitute for MDMA is not shared with DOM and is unusual among psychedelics, but is shared with α-ethyltryptamine (αET).^[15][16] In monkeys, Ariadne was found to possibly increase motivation, as it caused monkeys that had stopped running mazes to begin running them again.^[1] Ariadne has also been found to be effective in an animal model of Parkinson’s disease, where it reversed motor deficits similarly to levodopa.^[5]

Serotonin 5-HT_2A receptor agonists have been found to increase dopamine levels in the nucleus accumbens and other mesolimbic areas.^[5] Non-hallucinogenic serotonin 5-HT_2A receptor agonists like Ariadne may produce this effect without causing psychedelic effects.^[5] This action may underlie the preliminary observations of effectiveness of Ariadne in the treatment of parkinsonism in animals and humans.^[5]

Ariadne, also known as 4-methyl-2,5-dimethoxy-α-ethylphenethylamine, is a substituted phenethylamine and amphetamine derivative.^[1][2] It is the analogue of 2,5-dimethoxy-4-methylamphetamine (DOM) in which the α–methyl group has been replaced with an α-ethyl group and is the analogue of 2,5-dimethoxy-4-methylphenethylamine (2C-D) with an ethyl group substituted at the α carbon.^[5][1][2]

The chemical synthesis of Ariadne has been described.^[1][2][13]

Other related compounds include the 4C derivatives 4C-B (homologue of 2C-B and DOB), 4C-I (homologue of 2C-I and DOI), 4C-P (homologue of 2C-P and DOPR), 4C-T-2 (homologue of 2C-T-2 and Aleph-2), and 4C-TFM (homologue of 2C-TFM and DOTFM), among others.^[1][17][5] Unlike Ariadne, 4C-B has been reported to produce pronounced psychedelic effects, although generally milder than those of 2C-B or DOB.^[17] A higher homologue of Ariadne is 5C-D.^[5]

Ariadne was first synthesized by Alexander Shulgin in 1968 and he discovered its psychoactive effects in 1969.^[8][5][1] Shulgin reported that the drug was tested by Bristol Laboratories as an antidepressant, in an anecdote where he was explaining how human testing is invaluable (compared to animal testing) on drugs that change the state of the mind. He said, “Before they launched into a full multi-clinic study to determine whether it’s going to be worth the animal studies or not, every person on the board of directors took it.”^[6] In The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds (2011), he described it also being evaluated for increasing mental alertness in geriatric individuals, treating Parkinson’s disease, and treating psychosis and manic depression.^[2][5] The tentative commercial name of Ariadne was Dimoxamine.^[2] (R)-Ariadne was said to have completed phase 2 clinical trials and to have reached phase 3 trials, but the actual clinical data were never disclosed and further development was halted due to strategic economic reasons.^[8][5] However, according to journalist Hamilton Morris, the United States Central Intelligence Agency (CIA) may have had involvement in the discontinuation of Ariadne’s development.^[18]

Ariadne’s alternative name 4C-DOM or 4C-D stands for “four-carbon DOM”, whereas the name of 2C-D stands for “two-carbon DOM”.^[5] Another name of Ariadne is α-Et-2C-D, which stands for α-ethyl-2C-D.^[14] Racemic Ariadne is additionally known by the former developmental code name BL-3912, while the (R)-enantiomer of Ariadne (R)-Ariadne, is known by the former developmental code name BL-3912A.^[5][2]

Ariadne may be a controlled substance in Canada under phenethylamine blanket-ban language.^[19]

Ariadne is not an explicitly controlled substance in the United States as of 2011.^[2][3] However, as a positional isomer of DOET, it can be considered and is listed as a Schedule I controlled substance in this country similarly.^[3][20]